NCT04762992 - LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

July 30, 2026

Study Completion Date

December 30, 2026

Conditions

Fetal Growth RetardationPrematurityPre-Eclampsia

Interventions

DRUG

subcutaneous Enoxaparin

Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.

OTHER

standard of care

Obsteric standard of care.

Trial Locations (1)

1050-170

Centro de Diagnóstico Pré-Natal, Maternidade Dr. Alfredo da Costa, Centro Hospitalar Universitário de Lisboa Central, Lisbon